LigaChem Biosciences Inc. (KOSDAQ:141080)
 146,400
 +4,900 (3.46%)
  Oct 31, 2025, 3:30 PM KST
LigaChem Biosciences Revenue
LigaChem Biosciences had revenue of 32.62B KRW in the quarter ending June 30, 2025, with 6.06% growth. This brings the company's revenue in the last twelve months to 148.28B, up 94.55% year-over-year. In the year 2024, LigaChem Biosciences had annual revenue of 125.90B with 268.71% growth.
Revenue (ttm) 
 148.28B
Revenue Growth 
 +94.55%
P/S Ratio 
 34.75
Revenue / Employee 
 872.24M
Employees 
 170
Market Cap 
5.15T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 125.90B | 91.75B | 268.71% | 
| Dec 31, 2023 | 34.15B | 733.60M | 2.20% | 
| Dec 31, 2022 | 33.41B | 1.26B | 3.90% | 
| Dec 31, 2021 | 32.16B | -25.34B | -44.07% | 
| Dec 31, 2019 | 57.50B | 32.26B | 127.81% | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| Samsung Biologics | 5.03T | 
| Celltrion | 3.75T | 
| Yuhan | 2.17T | 
| Hanmi Pharm. | 1.47T | 
| SK Biopharmaceuticals | 620.28B | 
| PharmaResearch | 449.81B | 
| Sam Chun Dang Pharm. | 215.10B | 
| ALTEOGEN | 158.06B |